MOLECULAR PARTNERS ADS/1 (6ML0) - Total Liabilities
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has total liabilities worth €21.77 Million EUR (≈ $25.45 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 6ML0 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
MOLECULAR PARTNERS ADS/1 - Total Liabilities Trend (2021–2025)
This chart illustrates how MOLECULAR PARTNERS ADS/1's total liabilities have evolved over time, based on quarterly financial data. See 6ML0 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
MOLECULAR PARTNERS ADS/1 Competitors by Total Liabilities
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Motorcycle Holdings Ltd
AU:MTO
|
Australia | AU$236.97 Million |
|
Innate Pharma
NASDAQ:IPHA
|
USA | $84.39 Million |
|
Midas Minerals Ltd
AU:MM1
|
Australia | AU$287.49K |
|
ANDHRA PAPER LIMITED
NSE:ANDHRAPAP
|
India | Rs6.37 Billion |
|
American Well Corp
NYSE:AMWL
|
USA | $85.84 Million |
|
Avadh Sugar & Energy Limited
NSE:AVADHSUGAR
|
India | Rs7.55 Billion |
|
Sif Holding NV
AS:SIFG
|
Netherlands | €515.54 Million |
|
Takarék Jelzálogbank Nyrt
F:FH21
|
Germany | €682.66 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down MOLECULAR PARTNERS ADS/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 6ML0 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MOLECULAR PARTNERS ADS/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual total liabilities of MOLECULAR PARTNERS ADS/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €21.77 Million ≈ $25.45 Million |
+28.90% |
| 2024-12-31 | €16.89 Million ≈ $19.75 Million |
-22.95% |
| 2023-12-31 | €21.92 Million ≈ $25.63 Million |
-19.08% |
| 2022-12-31 | €27.09 Million ≈ $31.67 Million |
-58.56% |
| 2021-12-31 | €65.38 Million ≈ $76.43 Million |
-- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more